Vismodegib (GDC-0449)

For research use only.

Catalog No.S1082

144 publications

Vismodegib (GDC-0449) Chemical Structure

CAS No. 879085-55-9

Vismodegib (GDC-0449) is a potent, novel and specific hedgehog inhibitor with IC50 of 3 nM and also inhibits P-gp with IC50 of 3.0 μM in a cell-free assay.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 144 In stock
USD 90 In stock
USD 170 In stock
USD 370 In stock
USD 627 In stock
USD 1070 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Vismodegib (GDC-0449) has been cited by 144 publications

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Biological Activity

Description Vismodegib (GDC-0449) is a potent, novel and specific hedgehog inhibitor with IC50 of 3 nM and also inhibits P-gp with IC50 of 3.0 μM in a cell-free assay.
Targets
Hedgehog [1]
(Cell-free assay)
3 nM
In vitro

GDC-0449 targets the Hedgehog signaling pathway, blocking the activities of the Hedgehog-ligand cell surface receptors PTCH and/or SMO and suppressing Hedgehog signaling. GDC-0449 prevents multiple ATP-binding cassette (ABC) transporters. GDC-0449 also blocks ABCG2, Pgp, and MRP1-important ABC transporters associated with MDR. GDC-0449 is a potent inhibitor of ABC transporters, ABCG2/BCRP and ABCB1/Pgp, and is a mild inhibitor of ABCC1/MRP1. In ABCG2-overexpressing HEK293 cells, GDC-0449 increases retention of the fluorescent ABCG2 substrate BODIPY-prazosin and resensitizes these cells to mitoxantrone. In Madin-Darby canine kidney II cells engineered to overexpress Pgp or MRP1, GDC-0449 increases the retention of calcein-AM and resensitizes them to colchicine. GDC-0449 also resensitizes human non-small cell lung carcinoma cells NCI-H460/par and NCI-H460/MX20, which overexpress ABCG2 in response to mitoxantrone, to mitoxantrone, and to topotecan or SN-38. The IC50 values of GDC-0449 for prevention of ABCG2 and Pgp are about 1.4 μM and 3.0 μM, respectively. [2] GDC-0449 alters intracellular Ca2+ homeostasis and inhibits cell growth in cisplatin-resistant lung cancer cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
IGROV-1 M2T0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwMEeyOFgh|ryP NH:wTnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK|5USU6JRWK8M4E,
HCE-T MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmK2TWM2OD1zLkOyNlQ4KM7:TR?= NYfLflhwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd|NEG3M{c,W0GQR1XSQE9iRg>?
D-542MG NXvPNZV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV[4VmFwUUN3ME2xMlg3PzN5IN88US=> Mn3ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
23132-87 MmLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\Mbm9KSzVyPUSuOFAyPDdizszN M1PGVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
HDLM-2 M3:3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYKxVlVXUUN3ME24MlA1PzZ4IN88US=> MlqwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
ACN M2LpOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LQfWlEPTB;OD61NFExQSEQvF2= M4PyelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
HuO-3N1 NYPyN3JpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnjdZNQUUN3ME25MlYxOTB6IN88US=> MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O|M1OTdxJ{7TRW5ITVJ:L3G+
BHT-101 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTPZnBKSzVyPUGxMlM5KM7:TR?= MmLRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
KYSE-150 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXITWM2OD1zMT61PFQyKM7:TR?= NIj1XXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK|5USU6JRWK8M4E,
MC-IXC MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\6dVBEUUN3ME2xNk4zOjl{IN88US=> NXHFOItmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd|NEG3M{c,W0GQR1XSQE9iRg>?
D-423MG MlXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLzVI9KSzVyPUGyMlc3PTdizszN MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O|M1OTdxJ{7TRW5ITVJ:L3G+
NY NULFfXVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{H6dWlEPTB;MUSuPFkxOyEQvF2= NXm1[mw{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd|NEG3M{c,W0GQR1XSQE9iRg>?
HOS M4rxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXtVo9KSzVyPUG1MlY4OTlizszN M4P3SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
NB7 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTF3Lki5NUDPxE1? NWnXZYljRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd|NEG3M{c,W0GQR1XSQE9iRg>?
DMS-273 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTF4Lk[3NVMh|ryP Mn7zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
MDA-MB-361 M1j6e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2flbmlEPTB;MUeuNlcyOSEQvF2= NHHhTGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK|5USU6JRWK8M4E,
DU-145 MoC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;5N2lEPTB;MUiuN|Ih|ryP NH6wemY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK|5USU6JRWK8M4E,
NCI-H82 MmPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jS[2lEPTB;MUmuPFM5PiEQvF2= MkL0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
NCI-SNU-1 M1vKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\xTWM2OD1{MD6wNVk3KM7:TR?= MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O|M1OTdxJ{7TRW5ITVJ:L3G+
GCT MoXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH34T4FKSzVyPUKwMlg5OjRizszN Ml\uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
C2BBe1 NFLYOlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPocIpKSzVyPUKxMlExPThizszN MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O|M1OTdxJ{7TRW5ITVJ:L3G+
LB2241-RCC NHm5bodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7VTWM2OD1{MT64OFQyKM7:TR?= MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O|M1OTdxJ{7TRW5ITVJ:L3G+
COLO-829 NYHVWFQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnidoVKSzVyPUKyMlE5PzFizszN MnK1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
EW-11 M1jlbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTJ{LkiwNlIh|ryP Moe2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
NCI-H526 Mn2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLhN3pjUUN3ME2yN{41PzF5IN88US=> M1\DS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
SF295 M1rTTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYGwVFZnUUN3ME2yOE4xOjV{IN88US=> MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O|M1OTdxJ{7TRW5ITVJ:L3G+
D-566MG NUjNZ4hvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPzPXZGUUN3ME2yOU4zQTR|IN88US=> NGiydYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK|5USU6JRWK8M4E,
8505C NVTHeWdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fLXmlEPTB;MkWuOlM{OSEQvF2= M4\rSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
HT-29 MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYP1Zph3UUN3ME2yOk4xPDNzIN88US=> MonCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
NBsusSR MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\0eGlEPTB;Mk[uPFAxPiEQvF2= NX[3[ndTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd|NEG3M{c,W0GQR1XSQE9iRg>?
BV-173 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTJ6LkOxPFIh|ryP MnrrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
CTB-1 MmOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTNyLkGwN|Eh|ryP MlvLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
JAR Ml\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX[0[Xh7UUN3ME2zNk42OzdzIN88US=> NXH5UIFXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd|NEG3M{c,W0GQR1XSQE9iRg>?
CAMA-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzWdpJKSzVyPUOzMlQ3OTVizszN NIK0T2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK|5USU6JRWK8M4E,
CAL-51 NUS4[HlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTPTWM2OD1|ND63NVc3KM7:TR?= M4jObFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
A172 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\nTWM2OD1|Nz60PVIyKM7:TR?= NFPjTW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK|5USU6JRWK8M4E,
QIMR-WIL M2rpdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrN[5JKSzVyPUO4MlA4ODhizszN M4PvWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
AsPC-1 NU\WTItoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3ne2NKSzVyPUO4MlQ3PTFizszN M2XqdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
MKN7 NHPmfXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXK0Umc1UUN3ME2zPU4xODd7IN88US=> Mn74QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
ONS-76 MlTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HuNWlEPTB;NEOuN|A2PyEQvF2= MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O|M1OTdxJ{7TRW5ITVJ:L3G+
RS4-11 NIXLdZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrPTWM2OD12ND6wO|UzKM7:TR?= NHrGcWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK|5USU6JRWK8M4E,
NOS-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfOZndKSzVyPUS0MlYxOzFizszN NIPTNlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PzN2MUevK|5USU6JRWK8M4E,
A101D Mnm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTR2LkiwNlMh|ryP NWDt[Xc1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd|NEG3M{c,W0GQR1XSQE9iRg>?
HCC1806 M3jqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTR4LkGxOFgh|ryP NUfJOpl{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd|NEG3M{c,W0GQR1XSQE9iRg>?
CAL-27 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fMcGlEPTB;NEeuO|I1PiEQvF2= MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0O|M1OTdxJ{7TRW5ITVJ:L3G+
BT-549 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzMTWM2OD12OD61N|E2KM7:TR?= MlH1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
LCLC-97TM1 NV3XeoE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTmcYtQUUN3ME20PU4zPDF|IN88US=> NUj6XpBJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd|NEG3M{c,W0GQR1XSQE9iRg>?
A4-Fuk MnywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vhSGlEPTB;NEmuPFQ6KM7:TR?= Mm\rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFc{PDF5Lze+V2FPT0WUPD;hQi=>
OVCAR-4 M1fSV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDjbFRKSzVyPUWwMlA3ODFizszN M{TW[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ4OzRzNz:nQnNCVkeHUkyvZV4>
HD-MY-Z NI\FfWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfFXVhKSzVyPUWwMlc4PjRizszN NYjyRWtPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd|NEG3M{c,W0GQR1XSQE9iRg>?
NCI-H292 NHLOPXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPlTWM2OD13MD64O|U5KM7:TR?= NWnVeXI5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDd|NEG3M{c,W0GQR1XSQE9iRg>?
Sk-ChA-1  NULPVpRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfEbYRlOC5{NfMAl|UxKM7:TR?= MV[3NkBp NV3uT5dMUUN3ME23OE42PMLzMj61PO69VQ>? NFSxZWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe0NlQ5Oid-MkW3OFI1QDJ:L3G+
Mz-ChA-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXJSmoxNjJ34pETOVAh|ryP MVi3NkBp MUPJR|UxRTV2Lkm3xtE{NjR3zszN NXP0[YZ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OFI1QDJpPkK1O|QzPDh{PD;hQi=>
Smo-WT NHvLOpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jKO2lEPTEEoH;mJFE1yqCwTR?= NXLOZodERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPVEyODRpPkK0NlkyOTB2PD;hQi=>
Smo-D473H  MkK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPjTWM2OMLib3[gO{4yyqEQvF2= M1iwXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkmxNVA1Lz5{NEK5NVExPDxxYU6=
K562 NYS3U4dCTnWwY4Tpc44hSXO|YYm= MlrwNVAh|ryP NVvyfoVkPzJiaB?= MlrHdoVlfWOnczD0bIUh\XiycnXzd4lwdiCxZjDHcIkyyqB? NILJTVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxPVgzPCd-MkOzNVk5OjR:L3G+
T315I BCR-ABL BaF3 Mn;tSpVv[3Srb36gRZN{[Xl? NWLKcFNjOTBizszN MYm3NkBp MkLhdoVlfWOnczD0bIUh\XiycnXzd4lwdiCxZjDHcIkyyqB? M3GydVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{G5PFI1Lz5{M{OxPVgzPDxxYU6=
TF-1 BCR-ABL NXPHd2RITnWwY4Tpc44hSXO|YYm= M2WyOVExKM7:TR?= NF\rW4o4OiCq NUm5dGpjemWmdXPld{B1cGViZYjwdoV{e2mxbjDv[kBIdGlzwrC= MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzOUiyOEc,OjN|MUm4NlQ9N2F-
Shh-Light 2 MU\GeY5kfGmxbjDhd5NigQ>? MmjzNkBl[Xm| NHHYenBCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IGPtc{BqdiCvb4Xz[UBUcGhvTHnnbJQhOiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHNpcC2rbnT1Z4VlKEeuaUGtdoVxd3K2ZYKgZYN1cX[rdImgZYZ1\XJiMjDkZZl{KGK7IHT1ZYwudHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJI1mfGixZDygTWM2OCB;IECuNFAyPSEQvF2u NUDmUmh2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOlM2OjJpPkKzNFY{PTJ{PD;hQi=>
NIH/3T3 MYTGeY5kfGmxbjDhd5NigQ>? MlvwTY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC|aXfuZYxqdmdiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gcY92e2ViTlnIM|NVOyClZXzsd{BjgSCJbHmt[JVidC2udXPp[oVz[XOnIILldI9zfGW{IHHzd4F6NCCLQ{WwJF0hOC5yMEKzJO69VS5? MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF6MECxNkc,OjdzOECwNVI9N2F-
NIH/3T3 Light2 MXHGeY5kfGmxbjDhd5NigQ>? NXLWW5RkUW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W|ZTDOTWgwO1R|IFzp[4h1OiClZXzsd{BjgSCJbHmtcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCLQ{WwJF0hOC5yMEKzJO69VS5? NYDHcXhKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2PFgzPzhpPkK4Olg5Ojd6PD;hQi=>
Light2 NVy1UnNlTnWwY4Tpc44h[XO|YYm= MoGxOFghcHK| Ml;2TY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC|aXfuZYxqdmdicHH0bJdigSCrbjDtc5V{\SCOaXfoeFIh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IFfsbU1tfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFnDOVAhRSByLkCwNlQ3KM7:TT6= NYrw[olvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3N|k4OTRpPkK5O|M6PzF2PD;hQi=>
HEPM MlLlSpVv[3Srb36gZZN{[Xl? NYHKWohIUW6qaXLpeIlwdiCxZjDTTGghcW5iaIXtZY4hUEWSTTDj[YxteyCkeTDHcIkudHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJUmghRSByLkCwNlgh|ryPLh?= M1;6e|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{G2Nlk3Lz5zOUexOlI6PjxxYU6=
Shh Light2 NWr3eWJtTnWwY4Tpc44h[XO|YYm= NGKzWmxKdmirYnn0bY9vKG:oIGPITEBqdiCvb4Xz[UBUcGhiTHnnbJQzKGOnbHzzJIJ6KEeOST3y[ZNxd26|aY\lJIZqemWobImgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCLQ{WwJF0hOC5yMEOg{txONg>? NWfROHZ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmzNFkxQDBpPkG5N|A6ODhyPD;hQi=>
HEPM NH3KUoZHfW6ldHnvckBie3OjeR?= MnPOTY5pcWKrdHnvckBw\iCKZXTn[Yhw\yC|aXfuZYxqdmdiaX6gbJVu[W5iSFXQUUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5icnXj[ZB1d3JvbXXkbYF1\WRiR3zpNUBuWk6DIHX4dJJme3Orb36gZpkhemWyb4L0[ZIh\2WwZTDhd5NigSxiSV7IJF0hOC5yMEOg{txONg>? NI\HeHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEi3OVc1OSd-MkC4O|U4PDF:L3G+
C3H10T1/2 M17PdGZ2dmO2aX;uJIF{e2G7 M37ZRVIxKGi{cx?= MnnzTY5pcWKrdHnvckBw\iCVbX:gbY4hdW:3c3WgR|NJOTCWMT:yJINmdGy|IIXzbY5oKGi3bXHuJJJm[2:vYnnuZY51KFOKSDDhd5Nme3OnZDDhd{Bm\m[nY4Sgc44hW02RL2PITEB1emGwc3nlcpQhfHKjboPjdolxfGmxbnHsJIFkfGm4YYTpc44h[W[2ZYKgNlAhcHK|IHL5JGdtcS2udXPp[oVz[XOnIILldI9zfGW{IHHzd4F6NCCLQ{WwJF0hOC5yMEWg{txONg>? MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMESzOkc,OjR7MEC0N|Y9N2F-
NIH/3T3 M4\VR2Z2dmO2aX;uJIF{e2G7 MnPENlQhcHK| NWTDNWtbUW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W|ZTDOTWgwO1R|IHPlcIx{KG2nYYP1doVlKGGodHXyJFI1KGi{czDifUBIdGlvZIXhcEBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFnDOVAhRSByLkCwOUDPxE1w NWj0TGE2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4NVA2QTFpPkK3PFExPTlzPD;hQi=>
NIH3T3 NHq1cXBHfW6ldHnvckBie3OjeR?= MmPWOFghcHK| M4K1PWlvcGmkaYTpc44hd2Zic33vMY1m\GmjdHXkJIhm\GenaH;nJJNq\26jbHnu[{Bx[XSqd3H5JIlvKG2xdYPlJG5KUDOWMzDj[YxteyCneIDy[ZN{cW6pIFfSSU1NfWNicnXwc5J1\XJiZ3Xu[UBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHNCTy2rbnT1Z4VlKEeURT3MeYMhemWyb4L0[ZIh[WO2aY\peJkh[W[2ZYKgOFghcHK|IHL5JIx2dWmwZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFAvODB4IN88UU4> MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR7OUS4N{c,Ojl2OUm0PFM9N2F-
Shh-light2 NV7xSW92TnWwY4Tpc44h[XO|YYm= NE[yNWVKdmirYnn0bY9vKG:oIGPtc{1u\WSrYYTl[EBJcCC|aXfuZYxqdmdiaX6gbJVu[W5iU3joMYxq\2i2MjDj[YxteyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEmFNUCgQUAxNjByNzFOwG0v NXrFT2UyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyOlg2PTFpPkKyNlY5PTVzPD;hQi=>
HEK293 NVjiTFdtTnWwY4Tpc44h[XO|YYm= NU[1S3BGOiCqcoO= MYXEbZNxdGGlZX3lcpQhd2ZiQl;ETXB[NWyjYnXscIVlKGO7Y3zvdIFucW6nIH\yc40hcHWvYX6gV41wKHKnY3XweI9zKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[W[2ZYKgNkBpenNiYomg[ox2d3Knc3PlcoNmKG2rY4Lvd4NweHluIFnDOVAhRSByLkCwO{DPxE1w NV76cFBTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyOlg2PTFpPkKyNlY5PTVzPD;hQi=>
NIH3T3 NH;zc4pHfW6ldHnvckBie3OjeR?= MXLJcohq[mm2aX;uJI9nKGinZHflbI9oKHKnY3XweI9zKHOrZ37hcIlv\yCyYYToe4F6KGmwIH3veZNmKE6LSEPUN{Bk\WyuczD0doFve2[nY4Tl[EB4cXSqIFfsbU1z\XCxcoTldkBo\W6nIHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiSVO1NEA:KDBwMEC3NVch|ryPLh?= MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl{M{e2OUc,OjR7MkO3OlU9N2F-
NIH/3T3 MVLGeY5kfGmxbjDhd5NigQ>? M3rHVlQ5KGi{cx?= NWn4bHpXUW6qaXLpeIlwdiCxZjDI[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBud3W|ZTDOTWgwO1R|IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBUd26rYzDo[YRo\WixZz3pcoR2[2WmIFfsbUBtfWOrZnXyZZNmKGGldHn2bZR6KGGodHXyJFQ5KGi{czDifUBFfWGuLXz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhUUN3MDC9JFAvODB5MUeg{txONg>? NV[1NGQ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyOFk1QTRpPkOwNlQ6PDl2PD;hQi=>
NIH3T3 MnK3SpVv[3Srb36gZZN{[Xl? MX:0PEBpenN? MYXJcohq[mm2aX;uJI9nKGinZHflbI9oKHOrZ37hcIxqdmdiaX6gcY92e2ViTlnIN3Q{KGOnbHzzJJN1[WKueTD0doFve2[nY4Tl[EB4cXSqIFfsbU1tfWOrZnXyZZNmKGOxboP0dpVkfCCrbnP1ZoF1\WRiZn;yJFQ5KGi{czDifUBlfWGuIHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhUUN3MDC9JFAvODB5MjFOwG0v NFfUSlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkiyO|E{Pid-Mk[4NlcyOzZ:L3G+
NIH3T3 MnLESpVv[3Srb36gZZN{[Xl? NHfxPJU1QCCqcoO= M{T1OWlvcGmkaYTpc44hd2ZiU3;ubYMucW6mdXPl[EBp\WSpZXjv[{B{cWewYXzsbY5oKGmwIH3veZNmKE6LSEPUN{Bk\WyuczDh[pRmeiB2ODDodpMh[nliR3zpMYx2[2moZYLhd4UhemWyb4L0[ZIh[XO|YYmsJGlEPTBiPTCwMlAxPzJizszNMi=> MmjxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ6MkC1OVQoRjJ4OEKwOVU1RC:jPh?=
NIH3T3 NFnrTXRHfW6ldHnvckBie3OjeR?= NUHWR|dtPDhiaILz NWWxSWF7UW6qaXLpeIlwdiCxZjDTTGghe2mpbnHsbY5oKHCjdHj3ZZkhcW5ibX;1d4UhVkmKM2SzJINmdGy|IH3lZZN2emWmIHHmeIVzKDR6IHjyd{BjgSCJbHmtcJVkcW[ncnHz[UBz\XCxcoTldkBie3OjeTygTWM2OCB;IECuNFA4OiEQvF2u MlrlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzN{[zPVYoRjJ2MUe2N|k3RC:jPh?=
NIH/3T3 M2i1fWZ2dmO2aX;uJIF{e2G7 MkP3OFghcHK| M37pSWlvcGmkaYTpc44hd2ZiaHXk[4Vpd2dic3nncoFtcW6pIIDheIh4[XliaX6gcY92e2ViTlnIM|NVOyClZXzsd{Bi\nSncjC0PEBpenNiYomgS4xqNWy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygTWM2OCB;IECuNFA4OiEQvF2u NVvBW5dYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PFYzODNpPkK0OFg3OjB|PD;hQi=>
NIH/3T3 Ml2zSpVv[3Srb36gZZN{[Xl? M{DtWmlvcGmkaYTpc44hd2ZiaHXk[4Vpd2dic3nncoFtcW6pIIDheIh4[XliaX6gcY92e2ViTlnIM|NVOyClZXzsd{BjgSCJbHmxMYx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiSVO1NEA:KDBwMEC3NkDPxE1w MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRyNUewOEc,OjR2MEW3NFQ9N2F-
NIH/3T3 NYHTS4hlTnWwY4Tpc44h[XO|YYm= M3LXN2lvcGmkaYTpc44hd2ZiaHXk[4Vpd2dic3nncoFtcW6pIIDheIh4[XliaX6gcY92e2ViTlnIM|NVOyClZXzsd{Bk[XK{eXnu[{B{fGGkbImgeJJidnOoZXP0[YQhT2yrLYLldI9zfGW{IHPvcpN1enWldDDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGG|c3H5MEBKSzVyIE2gNE4xODd{IN88UU4> NHf2OFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[0NlExOSd-Mki2OFIyODF:L3G+
C3H10T1/2 MlrTSpVv[3Srb36gZZN{[Xl? NIXBepk3KGi{cx?= MYLJcohq[mm2aX;uJI9nKFODRz3pcoR2[2WmIHTp[oZmemWwdHnheIlwdiCxZjDtc5V{\SCvZYPlcoNpgW2jbDDwcJVzcXCxdHXueEBEO0hzMGSxM|Ih[2WubIOgeI8h[WytYXzpcoUheGixc4DoZZRie2VicH;zbZRqfmVib3Xz[Y9jdGG|dIOgZYZ1\XJiNjDodpMtKEmFNUCgQUAxNjBzMTFOwG0v NWPyV4tNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyOlg2PTFpPkKyNlY5PTVzPD;hQi=>
HCC827 MVnGeY5kfGmxbjDhd5NigQ>? MnrZSIl{eGyjY3Xt[Y51KG:oIGuzTH0u[3mlbH;wZY1qdmViZoLvcUBUVU9iVkSwOG0hdXW2YX70JIlvKGenZnn0bY5q[iC{ZYPpd5RidnRiaIXtZY4hUEOFOEK3JINmdGy|IHL5JJNkcW62aXzsZZRqd25iY3;1cpRqdmduIFvpJF0hOC5yMUKyJO69VS5? MoG0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5OEexOVYoRjJ6N{i3NVU3RC:jPh?=
C3H10T1/2 MlnFSpVv[3Srb36gZZN{[Xl? MkXvTY5pcWKrdHnvckBw\iCVSFigbY4hdW:3c3WgR|NJOTCWMT:yJINmdGy|IHL5JGdtcS2udXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGlEPTBiPTCwMlAyOyEQvF2u M2nWelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{G2Nlk3Lz5zOUexOlI6PjxxYU6=
S12 MVHGeY5kfGmxbjDhd5NigQ>? NWfxV4pKUW6qaXLpeIlwdiCxZjDI[YRo\WixZzDzbYdv[WyrbnegbY4hdW:3c3WgV|EzKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDy[YNmeHSxcj3t[YRq[XSnZDDHcIkyKG2UTlGg[ZhxemW|c3nvckBjgSC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJUmghRSByLkCxN{DPxE1w MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh5NUe0NUc,OjB6N{W3OFE9N2F-
TM3 NFu5UGhHfW6ldHnvckBie3OjeR?= NYPMW5ZjPDhiaILz NX\lR|ROUW6qaXLpeIlwdiCxZjDIbEB{cWewYXzpcocheGG2aIfhfUBqdiCvb4Xz[UBVVTNiY3XscJMh[XO|ZYPz[YQh[XNiZH;3cpJm\3WuYYTpc44hd2ZiR3zpNUBo\W6nIHX4dJJme3Orb36gZYZ1\XJiNEigbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3MDC9JFAvODF|IN88UU4> Mo\NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7N{[yNVUoRjJ4OUe2NlE2RC:jPh?=
NIH/3T3 M1XIeGZ2dmO2aX;uJIF{e2G7 MVHJcohq[mm2aX;uJI9nKGinZHflbI9oKHOrZ37hcIlv\yCyYYToe4F6KGmwIH3veZNmKE6LSD:zWFMh[2WubIOg[ZhxemW|c3nu[{B4cWymIIT5dIUhW22xIHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCJbHmgcXJPSSCneIDy[ZN{cW:wIHL5JHJVNVCFUjDt[ZRpd2RuIFnDOVAhRSByLkCxOFQh|ryPLh?= NVfTUJhYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4NVA2QTFpPkK3PFExPTlzPD;hQi=>
S12 NIXJVXZHfW6ldHnvckBie3OjeR?= NF20V4U1QCCqcoO= MkLnTY5pcWKrdHnvckBw\iCqdX3hckBUUEhicHH0bJdigSCrbjDtc5V{\SCVMUKgZ4VtdHNiYYPz[ZN{\WRiYYOgS2xKNW2nZHnheIVlKHS{YX7zZ5JqeHSrb37hcEBi[3Srdnn0fUBi\nSncjC0PEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCLQ{WwJF0hOC5yMUWg{txONg>? MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR|OEWyO{c,OjF2M{i1Nlc9N2F-
NIH/3T3 MXnGeY5kfGmxbjDhd5NigQ>? M4CxXGlvcGmkaYTpc44hd2ZiU13PJIlvKG2xdYPlJG5KUC9|VEOgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCVQVetbY5lfWOnZDDo[YRo\WixZz3t[YRq[XSnZDDseY1qdmW|Y3XuZ4Uhe2mpbnHsbY5oKGK7IFfSSU1tfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFnDOVAhRSByLkCxOkDPxE1w NGfkVmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGxPVUxOCd-Mk[xNVk2ODB:L3G+
U2OS MnG1SpVv[3Srb36gZZN{[Xl? NHfP[5YzKGi{cx?= MWrEbZNxdGGlZX3lcpQhd2ZiW{PIYYN6[2yxcHHtbY5mKG[{b32ge4lt\CC2eYDlJHNudyCneIDy[ZN{\WRiaX6gWVJQWyClZXzsd{Bi\nSncjCyJIhzeyCkeTDzZ4lvfGmubHH0bY9vKGOxdX70bY5oNCCNaTC9JFAvODF4MjFOwG0v NFjCc209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2N|UzOid-MkOwOlM2OjJ:L3G+
NIH3T3 M4OzO2Z2dmO2aX;uJIF{e2G7 M{SyNlMxKGi{cx?= NXfRUoZDUW6qaXLpeIlwdiCxZjDTcY8hemWlZYD0c5IhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iTlnIN3Q{KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gV41wKGGpb37pd5QhW0GJLXnu[JVk\WRiR2LFJIFkfGm4YYTpc44h[W[2ZYKgN|AhcHK|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiSVO1NEA:KDBwMEKzJO69VS5? NV\1PWZPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3NlY5ODdpPkK0O|I3QDB5PD;hQi=>
medulloblastoma cell MUDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M2LVWVM3KGi{cx?= NI\IU4xCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JHB1[2htLz2gZY5lKHB3Mz2vMUBud3W|ZTDt[YR2dGyxYnzhd5RwdWFiY3XscJMh[W[2ZYKgN|YhcHK|IHL5JGJz\HViaX7jc5Jxd3KjdHnvckBie3OjeTygTWM2OCB;IECuNFMxPCEQvF2u MlfTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4OEiyO|goRjJ6Nki4Nlc5RC:jPh?=
Shh Light2 MWPGeY5kfGmxbjDhd5NigQ>? M1XidGFvfGGpb37pd5Qh[WO2aY\peJkh[XRic33vc5Rp\W6nZDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W|ZTDTbIghVGmpaISyJINmdGy|IHPvMYV5eHKnc4PpcochT2yrLXTldIVv\GWwdDDy[ZBwenSncjDn[Y5mKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhUGhic3nncoFtcW6pIHL5JIR2[WxibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBKSzVyIE2gNE4xOzNizszNMi=> MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR7MUS1PUc,OjR2OUG0OVk9N2F-
Light2 M2DzUWZ2dmO2aX;uJIF{e2G7 NGDhWGZKdmirYnn0bY9vKG:oIHjl[IdmcG:pIIPp[45idGmwZzDwZZRpf2G7IHnuJI1wfXOnIFzp[4h1OiClZXzsd{BqdiCVaHigZ49v\Gm2aX;u[YQhdWWmaYXtJIJ6KEeuaT3seYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEmFNUCgQUAxNjB|OTFOwG0v M3PaelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEezN|A{Lz5{OEi3N|MxOzxxYU6=
Shh Light2 MUHGeY5kfGmxbjDhd5NigQ>? MkfwTY5pcWKrdHnvckBw\iCVbX:tcYVlcWG2ZXSgTIghe2mpbnHscIlv\yCyYYToe4F6KGmwIH3veZNmKFOqaDDMbYdpfDJiY3XscJMh[nliR3zpMYx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiSVO1NEA:KDBwMEO5NkDPxE1w NF;EOnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{ezOlA3Oyd-Mke3N|YxPjN:L3G+
ASZ001 M{n4SmZ2dmO2aX;uJIF{e2G7 M33zVFQ5KGi{cx?= MmjYTY5pcWKrdHnvckBw\iCKZXTn[Yhw\yC|aXfuZYxqdmdiaX6gcY92e2ViQWPaNFAyKGOnbHzzJIF{e2W|c3XkJIF{KGSxd37y[Yd2dGG2aX;uJI9nKEeuaUGgcXJPSSCneIDy[ZN{cW:wIHHmeIVzKDR6IHjyd{BjgSCUVD3QR3Ih[W6jbInzbZMtKEmFNUCgQUAxNjB2IN88UU4> M{\kW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwO|E3Lz5{NEmwNFcyPjxxYU6=
NIH/3T3 M3P3eWZ2dmO2aX;uJIF{e2G7 MlvuOFghcHK| MoLrRY51[WexbnnzeEBi[3Srdnn0fUBifCCVbX:gdoVk\XC2b4KgbY4hdW:3c3WgUmlJNzOWMzDj[YxteyCqYYLic5JqdmdiR2LFMWx2[yCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKFODRz3pcoR2[2WmIFjoJJNq\26jbHnu[{Bx[XSqd3H5JJBz\WmwY4XiZZRm\CC5aYToJINmdGy|IH\vcIxwf2WmIHL5JHNCTyCjZHTpeIlwdiCvZXHzeZJm\CCjZoTldkA1QCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR|UxKD1iMD6wOFYh|ryPLh?= MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTh3N{K3OUc,Ojl6NUeyO|U9N2F-
Light2 NFzsV3RHfW6ldHnvckBie3OjeR?= NF:3[oc{OCCqcoO= MVHJcohq[mm2aX;uJI9nKGinZHflbI9oKHOrZ37hcIlv\yCyYYToe4F6KGmwIH3veZNmKEyrZ3j0NkBk\WyuczDpckBUcGhiY3;u[Il1cW:wZXSgcYVlcXWvIHHmeIVzKDNyIHjyd{BjgSCJbHmtVoVvcWyuYTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEmFNUCgQUAxNjB3IN88UU4> NIe1WZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEC5PVI2Pyd-M{CwPVkzPTd:L3G+
C3H10T1/2 NUnpOXQ{TnWwY4Tpc44h[XO|YYm= NYfmZ3ZNPiCmYYnz MnTWTY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC|aXfuZYxqdmdicHH0bJdigS2vZXTpZZRm\CCmaX\m[ZJmdnSrYYTpc44hd2ZibX;1d4UhSzOKMUDUNU8zKGOnbHzzJIF{e2W|c3XkJIF{KGSnY4LlZZNmKGmwIGPBS{1qdmS3Y3XkJGFNWCCjY4Tpeol1gSCjZoTldkA3KGSjeYOgZpkh[2inbXnseY1qdmW|Y3XuZ4Uu[mG|ZXSgZZN{[XluIFnDOVAhRSByLkC1JO69VS5? M1iyXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEm5NlU4Lz5|MEC5PVI2PzxxYU6=
DaOY NWLiXlRyTnWwY4Tpc44h[XO|YYm= NW[yTopwPDhiaILz Mn7DTY5pcWKrdHnvckBw\iCKZXTn[Yhw\yC|aXfuZYxqdmdiaX6gbJVu[W5iRHHPXUBk\WyuczDhd5Nme3OnZDDhd{Bld3ewcnXneYxifGmxbjDv[kBIdGlzIH3SUmEh\XiycnXzd4lwdiCjZoTldkA1QCCqcoOgZpkhWlRvUFPSJIFv[Wy7c3nzMEBKSzVyIE2gNE4xQDZizszNMi=> M{GwTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwO|E3Lz5{NEmwNFcyPjxxYU6=
C3H10T1/2 M3nWXGZ2dmO2aX;uJIF{e2G7 NEmwZmwyKGi{ M2HxRmlvcGmkaYTpc44hd2ZiSHXk[4Vpd2dic3nncoFtcW6pIIDheIh4[XliaX6gcY92e2ViQ{PINVBVOS9{IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBxfXKvb4LwbIFucW6nLXnu[JVk\WRiaX7jdoVie2ViaX6gZYxs[WyrbnWgdIhwe3CqYYThd4UhdGW4ZXygeZNqdmdiQ1TQMZN1[XJiYYOgd5Vje3S{YYTlJJBz\XS{ZXH0[YQh\m:{IEGgbJIh\m:ubH;3[YQh[nlicIXycY9zeGijbXnu[UBi\GSrdHnvckBu\WG|dYLl[EBi\nSncjC1JIRigSxiSVO1NEA:KDBwMUSg{txONg>? MoHrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NEe5N|koRjJ6OUS3PVM6RC:jPh?=
M210B4 NY\2PJJvTnWwY4Tpc44h[XO|YYm= MVGyOEBpenN? NFXXPHVKdmirYnn0bY9vKG:oIFjl[IdmcG:pIIPp[45idGmwZzDpckBud3W|ZTDNNlExSjRiY3XscJMh[XO|ZYPz[YQh[XNiZH;3cpJm\3WuYYTpc44hd2ZiUITjbEBuWk6DIHX4dJJme3Orb36gZYZ1\XJiMkSgbJJ{KGK7IGLUMXBEWiCjbnHsfZNqeyxiSVO1NEA:KDBwMUSg{txONg>? NFnW[4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFcyPid-MkS5NFA4OTZ:L3G+
M210B4 NYPafVIyTnWwY4Tpc44h[XO|YYm= NUD4PHlCOjRiaILz MYfJcohq[mm2aX;uJI9nKEinZHflbI9oKHOrZ37hcIlv\yCrbjDtc5V{\SCPMkGwRlQh[2WubIOgZZN{\XO|ZXSgZZMh\G:5boLl[5Vt[XSrb36gc4YhT2yrMTDtVm5CKGW6cILld5Nqd25iYX\0[ZIhOjRiaILzJIJ6KFKWLWDDVkBidmGueYPpd{whUUN3MDC9JFAvOiEQvF2u NHvLcWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFcyPid-MkS5NFA4OTZ:L3G+
Shh Light2 NXy1SZZ{TnWwY4Tpc44h[XO|YYm= NF\sSYsyKGi{ M3fEUGlvcGmkaYTpc44hd2ZiSHXk[4Vpd2dic3nncoFtcW6pIHnuJI1wfXOnIGPobEBNcWeqdEKgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKHC3cn3vdpBp[W2rbnWtbY5lfWOnZDDHcIkhdWWmaXH0[YQhfHKjboPjdolxfGmxbnHsJIFkfGm4aYT5JJBz\XS{ZXH0[YQh\m:{IEGgbJIh\m:ubH;3[YQh[nlicIXycY9zeGijbXnu[UBi\GSrdHnvckBu\WG|dYLl[EBi\nSncjC0PEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCLQ{WwJF0hOC57ODFOwG0v MoTZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NEe5N|koRjJ6OUS3PVM6RC:jPh?=
NIH/3T3 NG\DT4FHfW6ldHnvckBie3OjeR?= NHLVeYJKdmirYnn0bY9vKG:oIHjl[IdmcG:pIIPp[45idGmwZzDwZZRpf2G7IHnuJI1wfXOnIF7JTE8{XDNiY3XscJMhcGG{Yn;ybY5oKFOvbzDEOFc4UCCvdYThcpQh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGdtcSCvUl7BJIV5eHKnc4Ppc44h[nliUmStVGNTKG2ndHjv[EwhUUN3MDC9JFEvOTl4IN88UU4> MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzhzMEW5NUc,Ojd6MUC1PVE9N2F-
S12 MV7GeY5kfGmxbjDhd5NigQ>? NXXhNY9tPDhiaILz NIDOephKdmirYnn0bY9vKG:oIHj1cYFvKFOKSDDwZZRpf2G7IHnuJI1wfXOnIGOxNkBk\WyuczDhd5Nme3OnZDDhd{BIVElvbXXkbYF1\WRidILhcpNkemmydHnvcoFtKGGldHn2bZR6KGGodHXyJFQ5KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XliaX6gdJJme2WwY3Wgc4YhOC53IH3nM41NKGi3bXHuJIFteGijLUGtZYNq\CCpbInjc5Bzd3SnaX6sJGlEPTBiPTCxMlc2KM7:TT6= NWP2cnVIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0N|g2OjdpPkKxOFM5PTJ5PD;hQi=>
Calu6 MVXGeY5kfGmxbjDhd5NigQ>? NYL1VHZyPCCqcoO= Mk\DVIxie22jIHPvcoNmdnS{YYTpc44hcW5iaIXtZY4hS2GudU[gZ4VtdHNieHXuc4dz[W[2ZXSgbY4hdnWmZTDtc5V{\SCjdDC3OUBu\y:tZzygdI8h[mmmIH3lZZN2emWmIHHmeIVzKDRiaILzJJBwe3RiZnnmeIgh\G:|ZTygR5AhRSB{MzFOwG0v NHn4NZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUexOlI6Pid-MUm3NVYzQTZ:L3G+
Calu-6 M2jFOGZ2dmO2aX;uJIF{e2G7 MlzQVIxie22jIHPvcoNmdnS{YYTpc44hcW5iQ3HseU03KGOnbHzzJJhmdm:pcnHmeIVlKG63ZHWgcY92e2ViUFuvVGQhdW:mZXygZZQhPzVibXevb4ctKHCxIHLp[EBnd3JiNTDkZZl{KG2nYYP1doVlKDRiaILzJJBwe3RibHHzeEBld3OnIILlcIF1cX[nIITvJJVvfHKnYYTl[EBkd262cn;sMEBEeCB;IEKzJO69VS5? MortQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6N{W3OFEoRjJyOEe1O|QyRC:jPh?=
T47D MWnDfZRwfG:6aXPpeJkh[XO|YYm= NYPyPFVDPzJiaILz NELl[|BEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBVPDeGIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUA1OS5|NDFOwG0v M{e1cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUC3OFI6Lz5{OUGwO|QzQTxxYU6=
LS180 NIm1OVhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NUHLWJF5PzJiaILz Ml\rRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCOU{G4NEBk\WyuczDh[pRmeiB5MjDodpMh[nlic4Xs[o9zcG:mYX3pcoUuSiCjc4PhfUwhUUN3MDC9JFQ2KM7:TT6= MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB7OUK1O{c,OzByOUmyOVc9N2F-
LS174T M{HNdWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MlTOO|IhcHK| MVnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEyVMUe0WEBk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4VvfCClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IES1MlgyKM7:TT6= NV3DXpNzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4NlA2PTRpPkK2PFIxPTV2PD;hQi=>
BxPC3 MmS2RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NF7Re484OiCqcoO= NULQV|N6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDCfHBEOyClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCudX3pcoV{[2WwdDDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQ4Njl3IN88UU4> NXLWOHRsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4NlA2PTRpPkK2PFIxPTV2PD;hQi=>
medulloblastoma cell NYnCNFhLSW62aYT1cY9zKGG|c3H5 M3OzW2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIH3l[JVtdG:kbHHzeI9u[SClZXzsd{B5\W6xZ4Lh[pRm\CCrbjDQeINpKCtxLTDtc5V{\SCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckB1fW2xcjD2c4x2dWViYYSgNVIvPSCvZz;r[{wheG9iYnnkMi=> M3nR[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{G2Nlk3Lz5zOUexOlI6PjxxYU6=
S12 M1XFdmZ2dmO2aX;uJIF{e2G7 M3zFclQ5KGi{cx?= NFjJUXFKdmirYnn0bY9vKG:oIHj1cYFvKFOKSDDwZZRpf2G7IHnuJI1wfXOnIGOxNkBk\WyuczDhd5Nme3OnZDDhd{BIVElvbXXkbYF1\WRidILhcpNkemmydHnvcoFtKGGldHn2bZR6KGGodHXyJFQ5KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XliaX6gdJJme2WwY3Wgc4YhOSCvZz;tUEBpfW2jbjDhcJBp[S1zLXHjbYQh\2y7Y3;wdo91\WmwLh?= NFXyNYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUSzPFUzPyd-MkG0N|g2Ojd:L3G+
Shh Light2 NVrQcIJjTnWwY4Tpc44h[XO|YYm= M3jpe|AvOSC3TR?= MkTVN|YhcHK| NI\QOZdKdmirYnn0bY9vKG:oIGPtc{1u\WSrYYTl[EBJcCC|aXfuZYxtcW6pIIDheIh4[XliaX6gcY92e2ViU3joJGxq\2i2MjDj[YxteyCjc4Pld5Nm\CCjczDzeZBxemW|c3nvckBw\iCJbHmxMY1TVkFiZYjwdoV{e2mxbjDheEAxNjFidV2gcYVie3W{ZXSgZYZ1\XJiM{[gbJJ{KGK7IGLUMZFRS1JiYX7hcJl{cXNw M1rmXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{O2NFY{Lz5{N{ezOlA3OzxxYU6=
SW1353 MYDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MmPtNVAhfU1? Mmm2OFghcHK| NFT6SHBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPXNVM2OyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjdDCxNEB2VSCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6Ng>? MnW2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2OUG0OVkoRjJ2NEmxOFU6RC:jPh?=
DaOY NWjhdllZSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M{DiNVExKHWP MVO0PEBpenN? NGDwT|hCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFThU3kh[2WubIOgZZN{\XO|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[XRiMUCgeW0h[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfU4> NGTiW|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES5NVQ2QSd-MkS0PVE1PTl:L3G+
A549 MlzYRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NInxfGoyOCC3TR?= MoXsOFghcHK| MofDRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDNUS5JINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIF1KDFyIIXNJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmu MoPuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2OUG0OVkoRjJ2NEmxOFU6RC:jPh?=
HCT116 Mmf2RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M3vIcFExKHWP NI\0Uo01QCCqcoO= NET2dlRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjdDCxNEB2VSCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6Ng>? MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR7MUS1PUc,OjR2OUG0OVk9N2F-
NIH/3T3 NFjFXotHfW6ldHnvckBie3OjeR?= M3y3ZVExKHWP NYHWPVdlUW6qaXLpeIlwdiCxZjDI[YRo\WixZzDzbYdv[WyrbnegbY4hdW:3c3WgUmlJNzOWMzDj[YxteyCjc4Pld5Nm\CCjczDkc5dvKHKnZ4XsZZRqd25ib3[gcXBVS0hzIH3SUmEh\XiycnXzd4lwdiCjdDCxNEB2VS5? MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR7MUS1PUc,OjR2OUG0OVk9N2F-
MSC NHP4XlhHfW6ldHnvckBie3OjeR?= MWGyNEB1dyB6MDD1US=> Mlq1TY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC|aXfuZYxqdmdiaX6gcY92e2ViTWPDJINmdGy|IHHzd4V{e2WmIHHzJIRwf25icnXneYxifGmxbjDv[kBidGujbHnu[UBxcG:|cHjheIF{\SCjdDCyNEB1dyB6MDD1UU4> MkXyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2OUG0OVkoRjJ2NEmxOFU6RC:jPh?=
SK-N-MC NYD0SJE4eUiWUzDhd5NigQ>? MYXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucz6= NEfBdGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
TC32 MnHWdWhVWyCjc4PhfS=> NUWwWnQyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXEN|MjDj[Yxtey5? MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
NIH3T3-Luc MUXGeY5kfGmxbjDhd5NigQ>? M1XnUVEhfU1? NV\jd|NvPDhiaILz NUH4W2NDUW6qaXLpeIlwdiCxZjDzcY8udWWmaXH0[YQhcGWmZ3Xoc4che2mpbnHsbY5oKHCjdHj3ZZkhcW5ibX;1d4UhVkmKM2SzMWx2[yClZXzsd{Bie3Onc4Pl[EBieyCmb4fudoVofWyjdHnvckBw\iCJbHmgcXJPSSCneIDy[ZN{cW:wIHH0JFEhfU1iYX\0[ZIhPDhiaILzJIJ6KHKnYXyteIlu\SCSQ2KgZY5idHm|aYOu M2rKZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEm5OFg{Lz5{OUS5PVQ5OzxxYU6=
C3H10T1/2 MVLGeY5kfGmxbjDhd5NigQ>? M2fkZlI1KGi{cx?= M36yTGlvcGmkaYTpc44hd2ZiaHXk[4Vpd2dic3nncoFtcW6pIIDheIh4[XlvbXXkbYF1\WRiR1zJNUBuWk6DIHX4dJJme3Orb36gbY4hdW:3c3WgR|NJOTCWMT:yJINmdGy|IHHmeIVzKDJ2IHjyd{BjgSCUVD3QR3Ih[W6jbInzbZMhcW5icILld4Vv[2Vib3[gLFFTNDOjUjy0V{w4[VJrLUfhMY1mfGi7bD2xMUgpWilvNj3t[ZRpgWyqZYD0ZY4uOi27bDnvZ5RicHmmcn:tNWgucW6mZX6tOE16dCB|LXj5[JJwgHmkZX76c4F1\S5? NXq1WpFJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3N|A6QDRpPkK0O|MxQTh2PD;hQi=>
C3H10T1/2 M2TQUmZ2dmO2aX;uJIF{e2G7 MWOyOEBpenN? M4DzO2lvcGmkaYTpc44hd2ZiaHXk[4Vpd2dic3nncoFtcW6pIIDheIh4[XlvbXXkbYF1\WRiR1zJNUBuWk6DIHX4dJJme3Orb36gbY4hdW:3c3WgR|NJOTCWMT:yJINmdGy|IHHmeIVzKDJ2IHjyd{BjgSCUVD3QR3Ih[W6jbInzbZMhcW5icILld4Vv[2Vib3[gWmQ{Ng>? MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd|MEm4OEc,OjR5M{C5PFQ9N2F-
NIH/3T3 MoHBSpVv[3Srb36gZZN{[Xl? MoHsNVAxKG6P NEG2T|M{PiCqcoO= MXvJcohq[mm2aX;uJI9nKGinZHflbI9oKHOrZ37hcIlv\yCyYYToe4F6KGmwIH3veZNmKE6LSD:zWFMh[2WubIOgZZN{\XO|ZXSgZZMh\G:5boLl[5Vt[XSrb36gc4YhW2iqLXnu[JVk\WRiR3zpNUBuWk6DIHX4dJJme3Orb36gcIV3\Wy|IHH0JFExOCCwTTDh[pRmeiB|NjDodpMh[nliUmStdXBEWiCjbnHsfZNqey5? NG\0OWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi3N|MxOyd-Mki4O|M{ODN:L3G+
C3H10T1/2 M4TYUWZ2dmO2aX;uJIF{e2G7 NYLBXFZYOTByIH7N NYTNdoxtOzZiaILz MYnJcohq[mm2aX;uJI9nKGinZHflbI9oKHOrZ37hcIlv\yCyYYToe4F6KGmwIH3veZNmKEN|SEGwWFEwOiClZXzsd{Bie3Onc4Pl[EBieyCmb4fudoVofWyjdHnvckBw\iCVaHitbY5lfWOnZDDHcIkyKG2UTlGg[ZhxemW|c3nvckBt\X[nbIOgZZQhOTByIH7NJIFnfGW{IEO2JIhzeyCkeTDSWE1yWEOUIHHuZYx6e2m|Lh?= NUfHOppPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4O|M{ODNpPkK4PFc{OzB|PD;hQi=>
NIH/3T3 Ml7LSpVv[3Srb36gZZN{[Xl? NWnFXG5pOTByIH7N Mme3N|YhcHK| M{nWVGlvcGmkaYTpc44hd2ZiaHXk[4Vpd2dic3nncoFtcW6pIIDheIh4[XliaX6gcY92e2ViTlnIM|NVOyClZXzsd{Bie3Onc4Pl[EBieyCmb4fudoVofWyjdHnvckBw\iCVaHitbY5lfWOnZDDweINpOSCvUl7BJIV5eHKnc4Ppc44hdGW4ZXzzJIF1KDFyMDDuUUBi\nSncjCzOkBpenNiYomgVnQueVCFUjDhcoFtgXOrcz6= MorEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6N{OzNFMoRjJ6OEezN|A{RC:jPh?=
C3H10T1/2 MVXGeY5kfGmxbjDhd5NigQ>? M3HmSlExOCCwTR?= M4HjW|M3KGi{cx?= M4rH[mlvcGmkaYTpc44hd2ZiaHXk[4Vpd2dic3nncoFtcW6pIIDheIh4[XliaX6gcY92e2ViQ{PINVBVOS9{IHPlcIx{KGG|c3Xzd4VlKGG|IHTve45z\We3bHH0bY9vKG:oIGPobE1qdmS3Y3XkJJB1[2hzIH3SUmEh\XiycnXzd4lwdiCuZY\lcJMh[XRiMUCwJI5OKGGodHXyJFM3KGi{czDifUBTXC2zUFPSJIFv[Wy7c3nzMi=> MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh5M{OwN{c,Ojh6N{OzNFM9N2F-
medulloblastoma cell M4HvbmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NVrxU2V{fXBidH:gN|AhfU1? NUfuTo5HPzJiaILz M3P5c2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViUITjbEswNSCyNUOtM{0hdWWmdXzsc4Jt[XO2b33hJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJBzd2yrZnXyZZRqd25idYCgeI8hOzBidV2gZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeT6= M4DFfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEezN|A{Lz5{OEi3N|MxOzxxYU6=
medulloblastoma cell MVXBdI9xfG:|aYOgZZN{[Xl? MmTRTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDtc5V{\SCSdHPoL{8uKHB3Mz2vMUBu\WS3bHzvZoxie3SxbXGgZ4VtdHNiaX3wcIFvfGWmIHnuJIF1cHmvaXOgcpVl\SCvb4Xz[UBifCBzMj61JI1oN2upLDDpdEBjcWRiZn;yJFE2KGOxboPlZ5V1cX[nIHThfZMh[nliVGXOSWwh[XO|YYmu NEXORpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi3N|MxOyd-Mki4O|M{ODN:L3G+
NIH/3T3 NFfJbI9HfW6ldHnvckBie3OjeR?= MlXQTY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC|aXfuZYxqdmdicHH0bJdigSCneIDy[ZN{\WRiaX6gcY92e2ViTlnIM|NVOyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJIhm\GenaH;nMYlv\HWlZXSgS4xqNTJiYXPjeY12dGG2aX;uJIF1KHSrcDDv[kBxemmvYYL5JINqdGmjIHL5JGRCWElic4ThbY5qdmdiYnHz[YQh[2:wZn;jZYwhdWmlcn;zZ49xcWNiYX7hcJl{cXNw MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzhzMEW5NUc,Ojd6MUC1PVE9N2F-
NIH/3T3 NULoWI5VTnWwY4Tpc44h[XO|YYm= MVPJcohq[mm2aX;uJI9nKGinZHflbI9oKHOrZ37hcIlv\yCyYYToe4F6KGmwIH3veZNmKE6LSD:zWFMh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDo[YRo\WixZz3pcoR2[2WmIGPtc{1GT0[SIHPpcIlienlidILhcpNtd2OjdHnvckBjgSCGQWDJJJN1[WmwaX7nJIJie2WmIHPvcoZw[2GuIH3pZ5Jwe2OxcHnjJIFv[Wy7c3nzMi=> M2fJS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OEGwOVkyLz5{N{ixNFU6OTxxYU6=
medulloblastoma cell M4jJVGFvfGlvdIXtc5Ih[XO|YYm= MkjkRY51cS22dX3vdkBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIGD0Z4gsNy1icEWzMU8uKG2nZIXscI9jdGG|dH;tZUBk\WyuczDpcZBt[W62ZXSgbY4h[XSqeX3pZ{BvfWSnIH3veZNmKGG|c3Xzd4VlKGG|IIT1cY9zKGe{b4f0bEBqdmirYnn0bY9vKGG2IEKwJI1oN2upLDDwc{Bi\G2rbnnzeIVz\WRidIfpZ4Uh\GGrbImgeoliKGejdnHn[UBu\WG|dYLl[EBmfmW{eTDveIhmeiCmYYmg[JVzcW6pIHPvcZBwfW6mIHTvd4lv\y5? NEfVTlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUezPVcyPCd-Mkm3N|k4OTR:L3G+
C3H10T1/2 MYjGeY5kfGmxbjDhd5NigQ>? NXfqWlRoPC5zIITvJFExODBibl2= MXnBcIxwe3SncnnjJIlvcGmkaYTpc44hd2ZiU33vJIlvKG2xdYPlJGM{UDFyVEGvNkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIID1do1wenCqYX3pcoUucW6mdXPl[EBIdGlzIITyZY5{[3KrcITpc45idCCjY4Tpeol1gSCjdDC0MlEhfG9iMUCwNEBvVSCkeTDxVGNzKGGwYXz5d4l{Ng>? M2\0R|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MEe0OVQyLz5{M{C3OFU1OTxxYU6=
C3H10T1/2 M{L1[WZ2dmO2aX;uJIF{e2G7 NGTq[5U1NjFidH:gNVAxOCCwTR?= M4[3ZWNwdXCndHn0bZZmKGmwaHnibZRqd25ib3[gV41wKGmwIH3veZNmKEN|SEGwWFEwOiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHNCTy2rbnT1Z4VlKEeuaUGgeJJidnOlcnnweIlwdmGuIHHjeIl3cXS7IHH0JFQvOSC2bzCxNFAxKG6PIHL5JJFRS1JiYX7hcJl{cXNw MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB5NEW0NUc,OjNyN{S1OFE9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Fas / DR4 / DR5 / Cleaved PARP / Bcl-2 / Cleaved caspase-3 / PDGFRα; 

PubMed: 22087285     


Pancreatic CSCs were treated with GDC-0449 (0, 1, 5 and 10 µM) for 48 h. The expression of Fas, DR4/TRAIL-R1, DR5/TRAIL-R2, PARP cleavage, Bcl-2, and Caspase-3 by the Western blot analysis. β-Actin was used as a loading control.

p-GSK3β / GSK3β / p-Akt / Akt / Gli1; 

PubMed: 27143997     


Cells were pretreated with or without 30 μM GDC-0449 for 2 h before TMT treatment. After incubation with 3.75 μM TMT for another 24 h, the expression levels of proteins were determined through Western blot analysis.

Gli1 / SOX2 / OCT4; 

PubMed: 26418365     


The activation of Hedgehog pathways and CSC markers were tested by immunoblotting analysis in Hs578T and BT549 cells. β‐Actin was used as a loading control.

p53 / Cyclin D1 / p21; 

PubMed: 28195165     


GDC-0449 treatment affected the expression levels of cell cycle-related protein levels. U251 cells were treated with 0.1% DMSO or GDC-0449 at the indicated concentrations for 24 h. Cells were then harvested and examined using Western blot analysis with the indicated antibodies.

Bcl-2 / Bax; 

PubMed: 28195165     


GDC-0449 treatment affected the expression levels of cell cycle-related protein levels. U251 cells were treated with 0.1% DMSO or GDC-0449 at the indicated concentrations for 24 h. Cells were then harvested and examined using Western blot analysis with the indicated antibodies.

22087285 27143997 26418365 28195165
Immunofluorescence
Gli1 / Gli2; 

PubMed: 22087285     


GDC-0449 inhibits expression of Gli1 and Gli2 in human pancreatic CSCs. The cells were seeded on fibronectin-coated coverslips and treated with GDC-0449 (10 µM) for 48 h. Subsequently, cells were fixed with 4% paraformaldehyde, blocked in 10% normal goat serum and stained with Gli1 and Gli2 primary antibodies (1∶100) for 16 h at 4°C and washed with PBS. Afterwards, cells were incubated with fluorescently labeled secondary antibody (1∶200) along with DAPI (1 mg/ml) for 1 h at room temperature and cells were mounted and visualized under a fluorescent microscope. For better visuality, the color of DAPI was changed from blue to red.

22087285
Growth inhibition assay
Cell viability; 

PubMed: 29042665     


GDC-0449 improves the anti-proliferation activity in NIH-3T3 cells but not in BxPC-3, Panc-1, MIAPaca-2 and SW1990 cells when cultured alone. The cytotoxicities of GDC-0449, Dox or Dox with GDC-0449 (5 μM or 10 μM) were measured by performing a 48-h MTT assay in BxPC-3 (A), Panc-1 (B), MIAPaca-2 (C), SW1990 (D) and NIH-3T3 (E) cells. Apoptosis rate was detected by flow cytometry (Annexin V staining) analysis after treatment with Dox (200 nM) with or without GDC-0449 for 24 h (F). Data are presented as the mean ± SD. *P < 0.05, **P < 0.01.

29042665
In vivo GDC-0449 has been used to treat medulloblastoma in animal models. [2] GDC-0449 prevents the growth of primary pancreatic xenografts without non-specifically inhibiting pancreatic cell proliferation. Oral dosing of GDC-0449 causes tumor regressions in the Ptch(+/-) allograft model of medulloblastoma at doses ≥25 mg/kg and tumor growth inhibition at doses up to 92 mg/kg dosed twice daily in two ligand-dependent colorectal cancer models, D5123, and 1040830. Analysis of Hh pathway activity and PK/PD modeling reveals that GDC-0449 inhibits Gli1 with a similar IC50 in both the medulloblastoma and D5123 models (0.165 μM and 0.267 μM, respectively). Pathway modulation is linked to efficacy using an integrated PK/PD model revealing a steep relationship where > 50% of the activity of GDC-0449 is associated with >80% repression of the Hh pathway. [4]

Protocol

Cell Research:[2]
- Collapse
  • Cell lines: MDCKII cells
  • Concentrations: 20 μM
  • Incubation Time: 2 hours
  • Method: MDCKII cells are seeded into 24-well plates at a density of 3 × 105 cells per well and are allowed to attach. Medium is then changed to that containing different drugs (50 μM VP, 50 μM indomethacin, or 20 μM GDC-0449 in DMSO or DMSO alone as control, and nonfluorescent calcein-AM is added to a final concentration of 1.0 μM and incubated at 37 °C for 2 hours. Cells are then washed twice with Ca2+, Mg2+-containing Hank's balanced salt solution buffer and lysed by shaking in 0.01% Triton X-100 in PBS buffer for 1 hour at room temperature or overnight at 4 °C. The lysate is then transferred into 96-well plates, and the fluorescence signal caused by the cell-derived calcein is quantified spectrophotometrically with a SpectraMax M5 Multi-Detection Readerusing an excitation wavelength of 495 nm and an emission wavelength of 515 nm. All manipulations are performed in the dark. All readings are expressed as mean ?SEM normalized to the control.
    (Only for Reference)
Animal Research:[4]
- Collapse
  • Animal Models: Ptch(+/-) allograft model, D5123 and 1040830
  • Dosages: ~ 100 mg/kg
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 84 mg/mL (199.38 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O
For best results, use promptly after mixing.
12.5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 421.3
Formula

C19H14Cl2N2O3S

CAS No. 879085-55-9
Storage powder
in solvent
Synonyms N/A
Smiles CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03610022 Recruiting Drug: Treatment with vismodegib Metastatic Basal Cell Carcinoma|Locally Advanced Basal Cell Carcinoma University Hospital Bordeaux September 3 2018 Phase 4
NCT03035188 Unknown status Drug: Vismodegib Basal Cell Carcinoma SRH Wald-Klinikum Gera GmbH January 2017 Phase 2
NCT02371967 Completed Drug: Vismodegib Basal Cell Carcinoma Hoffmann-La Roche April 8 2015 --
NCT02667574 Active not recruiting Drug: ERIVEDGE Basal Cell Carcinoma University Hospital Lille|Hoffmann-La Roche November 18 2014 Phase 2
NCT02067104 Terminated Drug: Vismodegib|Drug: Placebo Basal Cell Carcinomas University of Arizona February 17 2014 Phase 2
NCT01774253 Terminated Drug: Vismodegib Pontine Glioma Giselle SaulnierSholler|Phoenix Children''s Hospital|Atrium Health May 2013 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

Related Hedgehog/Smoothened Products

Tags: buy Vismodegib|Vismodegib ic50|Vismodegib price|Vismodegib cost|Vismodegib solubility dmso|Vismodegib purchase|Vismodegib manufacturer|Vismodegib research buy|Vismodegib order|Vismodegib mouse|Vismodegib chemical structure|Vismodegib mw|Vismodegib molecular weight|Vismodegib datasheet|Vismodegib supplier|Vismodegib in vitro|Vismodegib cell line|Vismodegib concentration|Vismodegib nmr|Vismodegib in vivo|Vismodegib clinical trial|Vismodegib inhibitor|Vismodegib Stem Cells & Wnt inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID